🇺🇸 FDA

Intelligence Platform

Patents

Browse 302 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9161936

Laquinimod for treatment of GABA mediated disorders

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9155775

Process for manufacturing glatiramer acetate product

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9107832

Risperidone microparticles formed by sublimation

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9102620

Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carbo

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9090598

Nilotinib salts and crystalline forms thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9063153

Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9018170

Reduced volume formulation of glatiramer acetate and methods of administration

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9012641

Crystalline forms of Prasugrel salts

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8993519

Method of treatment for neutropenia using stable formulations of recombinant human albumin

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8975279

Amine salts of laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8946167

Pharmaceutical compositions containing plasma protein

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8946300

Use of rasagilline for the treatment of restless legs syndrome

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8937082

Nilotinib salts and crystalline forms thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jan 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8920373

Reduced volume formulation of glatiramer acetate and methods of administration

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8889661

Treatment of lupus nephritis using laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8889213

Processes for coating a carrier with microparticles

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8889627

Treatment of multiple sclerosis with combination of laquinimod and fingolimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8865722

Wet formulations of aripiprazole

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8815511

Determination of single nucleotide polymorphisms useful to predict response for glatiramer

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8809310

Use of rasagiline for the treatment of multiple system atrophy

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8809537

N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8802854

Crystalline forms of Prasugrel salts

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8759314

Methods for treating multiple sclerosis using antisense oligonucleotides

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8759302

Methods of treating a subject afflicted with an autoimmune disease using predictive biomar

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted